Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAM01 in Healthy, Malaria-Naive Adults
NCT05891236Phase 1Completed
- Sponsor
- Gates Medical Research Institute
- Start
- Aug 2023
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MAM01 in malaria (10 arms), sponsored by Gates Medical Research Institute. Primary endpoints: Number of Participants Reporting Solicited Adverse Events, Number of Participants Reporting Unsolicited Adverse Events and 3 more. Started Aug 2023; status: completed.
02
Drugs
MAM01
03
Conditions
malaria
Beyond the preview
Go deeper on NCT05891236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05891236.